Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience

Noam Benyamini, MD, Adir S, MD, Moshe E. Gatt, MD, Yael C Cohen, MD, Irit Avivi, MD, Svetlana Trestman, MD, Olga Shvetz, MD, Tamar Tadmor, MD, Najib Dally, MD, Yevgeny Chober, Hila Magen, MD, Chezi Ganzel, MD, Osnat Jarchowcky Dolberg, Celia Suriu, MD, Noa Lavi, MD

Blood (2018) 132 (Supplement 1): 3259.

https://doi.org/10.1182/blood-2018-99-115985

Published: 2018

Journal Articles

Treatment Patterns and Clinical Outcomes in High-Risk Multiple Myeloma Patients Carrying the 17p Deletion: A Multi-Center Retrospective Observational Study

Yael Cohen, MD, Moshe E. Gatt, MD, Noa Lavi, MD, Chezi Ganzel, Hila Magen, MD, Irit Avivi, MD, Tamar Tadmor, MD, Celia Suriu, MD, Osnat Jarchowsky Dolberg, Amitai Papushado, MD, Svetlana Trestman, MD, Ron Ram, MD

Blood (2016) 128 (22): 4510.

https://doi.org/10.1182/blood.V128.22.4510.4510

Published: 2016

Journal Articles

High Peripheral Blood Circulating BDNF Levels Are Associated with Good Prognosis in CLL Patients; A CXCR-4 Dependent Effect?

David Azoulay, PhD, Yair Herishanu, MD, Mika Shapiro, PhD, Yarden Brenshaft, Celia Suriu, MD, Luiza Akria, MD, Andrei Braester, MD

Blood (2016) 128 (22): 5562.

https://doi.org/10.1182/blood.V128.22.5562.5562

Published: 2016

Journal Articles

Efficacy and Safety of Salvage Therapy Using Carfilzomib for Relapsed or Refractory Multiple Myeloma Patients: A Multicentre Retrospective Observational Study

Eli Muchtar, MD, Moshe Gatt, MD, Ory Rouvio, Chezi Ganzel, Evgeni Chubar, MD, Celia Suriu, MD, Tamar Tadmor, Olga Shevetz, MD, Noa Lavi, MD, Tzippy Shochat, MSc, Yael C Cohen, MD, Irit Avivi, MD, Pia Raanani, MD, Hila Magen, MD

Blood (2015) 126 (23): 5371.

https://doi.org/10.1182/blood.V126.23.5371.5371

Published: 2015

Journal Articles

Alterations in Platelet Levels of Brain-Derived Neurotrophic Factor Are Associated with Clinical Response to Bortezomib in Patients with Multiple Myeloma

David Azoulay, PhD, Celia Suriu, MD, Luiza Akria, MD, Netanel A Horowitz, MD, Andrei Braester, MD

Blood (2014) 124 (21): 2252.

https://doi.org/10.1182/blood.V124.21.2252.2252

Published: 2014

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience

Treatment Patterns and Clinical Outcomes in High-Risk Multiple Myeloma Patients Carrying the 17p Deletion: A Multi-Center Retrospective Observational Study

High Peripheral Blood Circulating BDNF Levels Are Associated with Good Prognosis in CLL Patients; A CXCR-4 Dependent Effect?

Efficacy and Safety of Salvage Therapy Using Carfilzomib for Relapsed or Refractory Multiple Myeloma Patients: A Multicentre Retrospective Observational Study

Alterations in Platelet Levels of Brain-Derived Neurotrophic Factor Are Associated with Clinical Response to Bortezomib in Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience

Treatment Patterns and Clinical Outcomes in High-Risk Multiple Myeloma Patients Carrying the 17p Deletion: A Multi-Center Retrospective Observational Study

High Peripheral Blood Circulating BDNF Levels Are Associated with Good Prognosis in CLL Patients; A CXCR-4 Dependent Effect?

Efficacy and Safety of Salvage Therapy Using Carfilzomib for Relapsed or Refractory Multiple Myeloma Patients: A Multicentre Retrospective Observational Study

Alterations in Platelet Levels of Brain-Derived Neurotrophic Factor Are Associated with Clinical Response to Bortezomib in Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only